New Phase 3 data for Romiplostim in Chemo-Induced Thrombocytopenia ✅ 84% of pts on Romiplostim maintained full chemo dose/schedule vs. 36% for placebo (OR 10.16). ✅ Targeted GI cancers (CRC, Gastric, Pancreatic). ✅ Low rate serious AEs. #Oncology #Hematology www.nejm.org/doi/full/10....